Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim vs filgrastim in AML patients after chemotherapy
IRCT20151020024625N8Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of pegfilgrastim and filgrastim in neutropenia and acute myeloid leukemia (AML) (2 arms), sponsored by Semnan University of Medical Sciences. Started Jan 2017; status: completed.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
neutropeniaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20151020024625N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151020024625N8.